These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 19861187

  • 1. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF.
    Vaccine; 2010 Jan 08; 28(3):692-8. PubMed ID: 19861187
    [Abstract] [Full Text] [Related]

  • 2. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
    Díaz-Ortega JL, Bennett JV, Castañeda D, Martinez D, de Castro JF.
    Vaccine; 2010 Oct 18; 28(44):7228-32. PubMed ID: 20800111
    [Abstract] [Full Text] [Related]

  • 3. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
    Díaz-Ortega JL, Bennett JV, Castañeda-Desales D, Quintanilla DM, Martínez D, de Castro JF.
    Vaccine; 2014 Jun 17; 32(29):3680-6. PubMed ID: 24837512
    [Abstract] [Full Text] [Related]

  • 4. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J.
    Vaccine; 2017 May 25; 35(23):3116-3122. PubMed ID: 28457672
    [Abstract] [Full Text] [Related]

  • 5. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S, Reibel S, Lang AB, Struck MM, Finkel B, Gerike E, Tischer A, Gassner M, Glück R, Stück B, Cryz SJ.
    Vaccine; 1998 May 25; 16(2-3):298-304. PubMed ID: 9607046
    [Abstract] [Full Text] [Related]

  • 6. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 25; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 7. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.
    Pediatr Infect Dis J; 2005 Dec 25; 24(12):1083-8. PubMed ID: 16371870
    [Abstract] [Full Text] [Related]

  • 8. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.
    Bone Marrow Transplant; 2004 Jun 25; 33(12):1187-90. PubMed ID: 15077129
    [Abstract] [Full Text] [Related]

  • 9. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, Ladyman C, Serralha M, Sadowska A, Loh R, Wesselingh SL, Sly PD, Holt PG.
    Vaccine; 2007 Feb 26; 25(10):1764-70. PubMed ID: 17224218
    [Abstract] [Full Text] [Related]

  • 10. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL, Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA.
    Hum Immunol; 2005 Jul 26; 66(7):788-98. PubMed ID: 16112026
    [Abstract] [Full Text] [Related]

  • 11. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A, Gerike E.
    Vaccine; 2000 Jan 31; 18(14):1382-92. PubMed ID: 10618536
    [Abstract] [Full Text] [Related]

  • 12. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K, Goa KL.
    Drugs; 2003 Jan 31; 63(19):2107-26. PubMed ID: 12962524
    [Abstract] [Full Text] [Related]

  • 13. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM.
    Saudi Med J; 2006 Jan 31; 27(1):63-9. PubMed ID: 16432596
    [Abstract] [Full Text] [Related]

  • 14. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, Yamamura AM, Martins RM, Leal Mde L, Collaborative Group for the Study of Yellow Fever Vaccines.
    Vaccine; 2011 Aug 26; 29(37):6327-34. PubMed ID: 21640779
    [Abstract] [Full Text] [Related]

  • 15. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 16. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct 01; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 17. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.
    J Infect Dis; 2008 Apr 01; 197(7):950-6. PubMed ID: 18419470
    [Abstract] [Full Text] [Related]

  • 18. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
    Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD.
    Vaccine; 2010 Feb 10; 28(6):1566-74. PubMed ID: 20003918
    [Abstract] [Full Text] [Related]

  • 19. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP.
    Cent Eur J Public Health; 2000 Aug 10; 8(3):160-3. PubMed ID: 10965439
    [Abstract] [Full Text] [Related]

  • 20. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I.
    J Infect Dis; 2012 Nov 15; 206(10):1542-8. PubMed ID: 22966129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.